£4.3M
The seed round was co-led by Boehringer Ingelheim Venture Fund and Scottish Enterprise to support laboratory establishment and team expansion.
GT
Glox Therapeutics
Glox Therapeutics develops precision antibiotic therapies to combat antimicrobial resistance.
£4.3MTotal raised
Glox Therapeutics develops precision antibiotic therapies using naturally occurring bacteriocins to target antimicrobial-resistant pathogens. The company emerged as a spin-out from the Universities of Glasgow and Oxford.
Categories
Founders
DW
Daniel Walker
Professor
CK
Colin Kleanthous
Professor